# SBI Japan-Israel Innovation Fund

> SBI Japan-Israel Innovation Fund is a VC fund backing Biotechnology. See 11 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Herzliya, Israel
- Total investments: 11
- Last investment: Oct 2024
- Lead investor: 9%
- Last updated: Aug 2026
- Website: http://sbi-ji.co.il/

SBI Japan-Israel Innovation Fund is a VC fund in Herzliya focused on Biotechnology and Health Care. SBI JI Innovation Fund is a biopharma focused VC. They were formed in early 2017 as a partnership between SBI Holdings of Japan and Vertex. SBI Holdings is a leading Japanese-based, financial services group. Vertex is a global venture capital firm with $700 million under management that boast an impressive track record of exits through M&A andIPO.

## Contacts

5 contacts available for SBI Japan-Israel Innovation Fund. Shizune tracks 1 team members at SBI Japan-Israel Innovation Fund. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/sbi-japan-israel-innovation-fund?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 6 | 55% |
| Health Care | 5 | 45% |
| Pharmaceutical | 5 | 45% |
| Therapeutics | 2 | 18% |
| Medical | 1 | 9% |

11 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 6 | 55% |
| Series C | 3 | 27% |
| Series A | 1 | 9% |
| Series D | 1 | 9% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Israel | 6 | 55% |
| United States | 2 | 18% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| David Ben-Ami | General Partner | 0 | https://shizune.co/investors/profile/david-ben-ami |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Secret Double Octopus | Secret Double Octopus is the developer of a security authentication platform that offers end users and security teams the simplicity and security of robust password-less authentication. The company's platform provides high-assurance access to a variety of resources, including workstations, networks, cloud, mobile, and legacy applications, byreplacing traditional passwords with a simple and secure password-free authentication process, allowing businesses to conduct and maintain their privacy efficiently. |  | Series C | Oct 28, 2024 |  |
| Orasis Pharmaceuticals | Orasis Pharmaceuticals develops a corrective eye drop to treat presbyopia. The company's product, CSF-1, is an eye drop that improves the quality of life for people with presbyopia by alleviating the burden of reading glasses. By repurposing existing and well-studied molecules, CSF-1 is designed to be effective and also safe, comfortable, andeasy-to-use. | $68M | Series D | Oct 08, 2024 |  |
| Orasis Pharmaceuticals | Orasis Pharmaceuticals develops a corrective eye drop to treat presbyopia. The company's product, CSF-1, is an eye drop that improves the quality of life for people with presbyopia by alleviating the burden of reading glasses. By repurposing existing and well-studied molecules, CSF-1 is designed to be effective and also safe, comfortable, andeasy-to-use. | $30M | Series C | Sep 10, 2020 |  |
| BioSight | BioSight is a biopharmaceutical private company founded in 2000 and re launched in mid 2009, revolutionizing the research and development of innovative cancer targeted pro-drugs. BioSight has developed technology S2DOT TM and a pipeline of targeted pro-drugs, that can target and release chemotherapy drugs inside cancer cells, while significantlyminimizing the systemic toxicity associated with conventional chemotherapy ​​treatments.​​​ | $19M | Series C | Mar 11, 2020 |  |
| Ayala Pharmaceuticals | Ayala Pharmaceuticals is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. Ayala’s approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through acombination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company has two product candidates under development, AL101 and AL02, targeting the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat a variety of tumors including Adenoid Cystic Carcinoma, Triple Negative Breast Cancer, T-cell Acute Lymphoblastic Leukemia, Desmoid Tumors and Multiple Myeloma (in collaboration with Novartis). | $30M | Series B | May 28, 2019 |  |
| BIOMx | BiomX discovers and develops innovative microbiome therapeutics. The Company's mission is to develop novel therapeutics for preventing and treating diseases in which microbiome imbalances have been implicated. BiomX's microbiome modulation technologies are based on the cutting-edge innovative research of its scientific collaborators:Professor Rotem Sorek, PhD and Dr. Eran Elinav, MD, PhD both of the Weizmann Institute of Science and Professor Timothy K. Lu, MD, PhD of the Massachusetts Institute of Technology. | $32M | Series B | Feb 20, 2019 |  |
| Biond Biologics | Biond Biologics is a discovery and development company in the prosperous and evolving field of cancer immunotherapy and autoimmune disorders. Biond aims to translate high quality science into breakthrough therapies that will address unmet medical needs while focusing on innovative drugs. Biond is an Israeli company located at Galilee region,combining excellent science and out of the box innovation. | $17M | Series B | Jan 08, 2019 |  |
| Orasis Pharmaceuticals | Orasis Pharmaceuticals develops a corrective eye drop to treat presbyopia. The company's product, CSF-1, is an eye drop that improves the quality of life for people with presbyopia by alleviating the burden of reading glasses. By repurposing existing and well-studied molecules, CSF-1 is designed to be effective and also safe, comfortable, andeasy-to-use. | $13M | Series B | Jun 05, 2018 |  |
| Chemomab | Chemomab is a clinical-stage biotech company focusing on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need. Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody designed to bind and blockCCL24 activity. CM-101 has potential to treat multiple severe and life-threatening inflammatory and fibrotic diseases and is currently undergoing clinical development with primary focus for the orphan diseases, Primary Sclerosing Cholangitis (PSC) and Systemic Sclerosis (SSc). Chemomab is advancing in parallel three Phase 2 clinical trials with CM-101 in fibrotic indications and expecting to report data during 2021-2022. | $10M | Series B | Dec 04, 2017 |  |
| LogicBio Therapeutics | LogicBio develops gene therapy vectors for previously incurable genetic and infectious diseases, including: hemophilia, HIV/AIDS and methylmalonic acidemia (MMA). Our proprietary technology based on the non-pathogenic Adeno-Associated Viral (AAV) vector offers superior efficiency and safety compared to all competitors on the market, and isuniquely suited for the treatment of children as well as adults. | $45M | Series B | Jun 29, 2017 |  |

10 of 11 investments shown.

## Co-investors
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 4 deals together
- [Israel Biotech Fund](https://shizune.co/investors/profile/israel-biotechfund) — VC Fund, 3 deals together
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund, 3 deals together
- [Visionary Venture Fund](https://shizune.co/investors/profile/visionary-venture-fund) — VC Fund, 3 deals together
- [Bluestem Capital](https://shizune.co/investors/profile/bluestem-capital) — VC Fund, 2 deals together
- [Harel Insurance and Financial](https://shizune.co/investors/profile/harel-insurance-investments-and-financial-services) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does SBI Japan-Israel Innovation Fund invest in?

SBI Japan-Israel Innovation Fund invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Series B and Series C stage. Most of the 11 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact SBI Japan-Israel Innovation Fund?

Public channels for SBI Japan-Israel Innovation Fund include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at SBI Japan-Israel Innovation Fund?

The team at SBI Japan-Israel Innovation Fund includes David Ben-Ami (General Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co